Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
Part of paid clinical trials in New York, New York.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT05390827
- Status
- Recruiting
Conditions
- Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.
Key Dates
- Start date
- May 19, 2022
- Status verified
- Feb 2026
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 3,644 participants (estimated)
Primary Outcome Measure
establish a mechanism within the institution to prospectively collect / extract digital remote physiological data among patients with cancer [ Time Frame: 1 year ]
Central Contacts
- Luke Pike, MD, DPhil212-639-8157
- Jessica Scott, PhD646-888-8093
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Luke Pike, MD, DPhil 212-639-8157 Jessica Scott, PhD 646-888-8093 Luke Pike, MD, DPhil (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
By research site
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Umbilical Cord Blood Transplantation From Unrelated DonorsRecruiting · University of Rochester · Rochester, New York
- Psychotherapy Intervention for Latinos With Advanced CancerRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid TumorsPHASE1 · Recruiting · Oxford BioTherapeutics Ltd · Phoenix, Arizona